Colchicine: effects upon urinary hydroxyproline excretion in patients with scleroderma.

Area of Science:

• Biochemistry
• Rheumatology

Background:

• Scleroderma is a fibrotic disease characterized by excessive collagen deposition.
• Colchicine has been suggested to potentially modulate collagen metabolism.

Purpose of the Study:

• To investigate the effect of intravenous colchicine on collagen turnover in scleroderma patients.
• To evaluate colchicine's impact on collagen synthesis and resorption.

Main Methods:

• Three scleroderma patients received intravenous colchicine (2-4 mg/day) for three days.
• Assessed 24-hour urine collections for total hydroxyproline (HYPRO) and nondialyzable polypeptide HYPRO.
• Analyzed hydroxylysyl-galactosyl-glucose (HGG) to hydroxylysyl-galactose (HG) ratios.

Main Results:

• Total urinary HYPRO (collagen resorption index) decreased during colchicine infusion.
• Nondialyzable polypeptide HYPRO (collagen synthesis index) showed a slight percentage increase.
• Hydroxylysyl-galactosyl-glucose to hydroxylysyl-galactose ratios did not show significant changes.

Conclusions:

• Colchicine administration in tolerated doses appears to diminish total body collagen catabolism without reducing collagen synthesis.
• Current data do not support the hypothesis that colchicine inhibits collagen synthesis or increases mature collagen degradation.
• These findings do not support the use of colchicine for treating fibrotic conditions like scleroderma based on its effects on collagen metabolism.